tetano
Editor, Senior Moderator
Int J Med Sci
. 2022 May 9;19(5):834-841.
doi: 10.7150/ijms.71132. eCollection 2022.
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
Yasuhito Suzuki[SUP] 1 [/SUP], Yoko Shibata[SUP] 1 [/SUP], Hiroyuki Minemura[SUP] 1 [/SUP], Takefumi Nikaido[SUP] 1 2 [/SUP], Yoshinori Tanino[SUP] 1 [/SUP], Atsuro Fukuhara[SUP] 1 3 [/SUP], Ryuzo Kanno[SUP] 4 [/SUP], Hiroyuki Saito[SUP] 5 [/SUP], Shuzo Suzuki[SUP] 5 [/SUP], Taeko Ishii[SUP] 6 [/SUP], Yayoi Inokoshi[SUP] 6 [/SUP], Eiichiro Sando[SUP] 7 [/SUP], Hirofumi Sakuma[SUP] 8 [/SUP], Tatsuho Kobayashi[SUP] 9 [/SUP], Hiroaki Kume[SUP] 3 [/SUP], Masahiro Kamimoto[SUP] 10 [/SUP], Hideko Aoki[SUP] 11 [/SUP], Akira Takama[SUP] 12 [/SUP], Takamichi Kamiyama[SUP] 13 [/SUP], Masaru Nakayama[SUP] 14 [/SUP], Kiyoshi Saito[SUP] 15 [/SUP], Koichi Tanigawa[SUP] 16 [/SUP], Masahiko Sato[SUP] 17 [/SUP], Toshiyuki Kanbe[SUP] 18 [/SUP], Norio Kanzaki[SUP] 19 [/SUP], Teruhisa Azuma[SUP] 20 [/SUP], Keiji Sakamoto[SUP] 21 [/SUP], Yuichi Nakamura[SUP] 21 [/SUP], Hiroshi Ohtani[SUP] 22 [/SUP], Mitsuru Waragai[SUP] 23 [/SUP], Shinsaku Maeda[SUP] 24 [/SUP], Tokiya Ishida[SUP] 25 [/SUP], Keishi Sugino[SUP] 26 [/SUP], Yasuhiko Tsukada[SUP] 27 [/SUP], Ryuki Yamada[SUP] 1 [/SUP], Riko Sato[SUP] 1 [/SUP], Takumi Onuma[SUP] 1 [/SUP], Hikaru Tomita[SUP] 1 [/SUP], Mikako Saito[SUP] 1 [/SUP], Natsumi Watanabe[SUP] 1 [/SUP], Mami Rikimaru[SUP] 1 [/SUP], Takaya Kawamata[SUP] 1 [/SUP], Takashi Umeda[SUP] 1 [/SUP], Julia Morimoto[SUP] 1 [/SUP], Ryuichi Togawa[SUP] 1 [/SUP], Yuki Sato[SUP] 1 [/SUP], Junpei Saito[SUP] 1 [/SUP], Kenya Kanazawa[SUP] 1 [/SUP], Ken Iseki[SUP] 27 [/SUP]
Affiliations
Abstract
Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan. Methods: We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635). Results: The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263-0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021). Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.
Keywords: COVID-19; Delta variant; SARS-CoV-2; casirivimab-imdevimab; real-world effectiveness.
. 2022 May 9;19(5):834-841.
doi: 10.7150/ijms.71132. eCollection 2022.
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
Yasuhito Suzuki[SUP] 1 [/SUP], Yoko Shibata[SUP] 1 [/SUP], Hiroyuki Minemura[SUP] 1 [/SUP], Takefumi Nikaido[SUP] 1 2 [/SUP], Yoshinori Tanino[SUP] 1 [/SUP], Atsuro Fukuhara[SUP] 1 3 [/SUP], Ryuzo Kanno[SUP] 4 [/SUP], Hiroyuki Saito[SUP] 5 [/SUP], Shuzo Suzuki[SUP] 5 [/SUP], Taeko Ishii[SUP] 6 [/SUP], Yayoi Inokoshi[SUP] 6 [/SUP], Eiichiro Sando[SUP] 7 [/SUP], Hirofumi Sakuma[SUP] 8 [/SUP], Tatsuho Kobayashi[SUP] 9 [/SUP], Hiroaki Kume[SUP] 3 [/SUP], Masahiro Kamimoto[SUP] 10 [/SUP], Hideko Aoki[SUP] 11 [/SUP], Akira Takama[SUP] 12 [/SUP], Takamichi Kamiyama[SUP] 13 [/SUP], Masaru Nakayama[SUP] 14 [/SUP], Kiyoshi Saito[SUP] 15 [/SUP], Koichi Tanigawa[SUP] 16 [/SUP], Masahiko Sato[SUP] 17 [/SUP], Toshiyuki Kanbe[SUP] 18 [/SUP], Norio Kanzaki[SUP] 19 [/SUP], Teruhisa Azuma[SUP] 20 [/SUP], Keiji Sakamoto[SUP] 21 [/SUP], Yuichi Nakamura[SUP] 21 [/SUP], Hiroshi Ohtani[SUP] 22 [/SUP], Mitsuru Waragai[SUP] 23 [/SUP], Shinsaku Maeda[SUP] 24 [/SUP], Tokiya Ishida[SUP] 25 [/SUP], Keishi Sugino[SUP] 26 [/SUP], Yasuhiko Tsukada[SUP] 27 [/SUP], Ryuki Yamada[SUP] 1 [/SUP], Riko Sato[SUP] 1 [/SUP], Takumi Onuma[SUP] 1 [/SUP], Hikaru Tomita[SUP] 1 [/SUP], Mikako Saito[SUP] 1 [/SUP], Natsumi Watanabe[SUP] 1 [/SUP], Mami Rikimaru[SUP] 1 [/SUP], Takaya Kawamata[SUP] 1 [/SUP], Takashi Umeda[SUP] 1 [/SUP], Julia Morimoto[SUP] 1 [/SUP], Ryuichi Togawa[SUP] 1 [/SUP], Yuki Sato[SUP] 1 [/SUP], Junpei Saito[SUP] 1 [/SUP], Kenya Kanazawa[SUP] 1 [/SUP], Ken Iseki[SUP] 27 [/SUP]
Affiliations
- PMID: 35693744
- PMCID: PMC9149641
- DOI: 10.7150/ijms.71132
Abstract
Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan. Methods: We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635). Results: The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263-0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021). Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.
Keywords: COVID-19; Delta variant; SARS-CoV-2; casirivimab-imdevimab; real-world effectiveness.